Indonesia Next Generation Sequencing Market Size, Share, Trends & Forecast Analysis by Offering, Application, and End User - Forecast to 2036

The Indonesia Next-Generation Sequencing (NGS) Market is estimated to be valued at USD 75.60 million in 2026 and is projected to reach USD 275.39 million by 2036, expanding at a CAGR of 13.8% during the forecast period. The market was valued at USD 66.30 million in 2025. The report provides a comprehensive evaluation of the rapidly developing NGS market in Indonesia by examining market trends, technological advancements, government genomics initiatives, healthcare applications, regulatory developments, competitive developments, and future growth opportunities across clinical, research, agricultural, and aquaculture applications.

Next-generation sequencing comprises high-throughput technologies that determine the sequence of nucleotides across multiple DNA or RNA fragments simultaneously. These technologies enable targeted gene panels, whole-exome sequencing, whole-genome sequencing, and RNA sequencing and are increasingly being applied across clinical diagnostics, oncology, reproductive health, infectious disease surveillance, rare disease research, drug discovery, agriculture, and animal research. The expansion of Indonesia's national genomics infrastructure, population genomics initiatives, and precision medicine programs is increasing demand for sequencing systems, consumables, sample preparation technologies, bioinformatics solutions, and commercial sequencing services.

Indonesia's genomics ecosystem is undergoing significant transformation through government investment and the development of domestic sequencing capabilities. The national genomics program has expanded the country's sequencing infrastructure from approximately 12 machines to around 60 machines, while the Ministry of Health has added 48 whole-genome sequencing machines across national referral hospitals. The development of ten Ministry of Health vertical hospitals, ten specialized genomics centers, and a broader network of 29 laboratories is further strengthening the country's domestic sequencing infrastructure.

This report delivers an in-depth assessment of the Indonesian NGS market by analyzing technological developments, government-funded genomics programs, clinical adoption trends, research applications, regulatory requirements, healthcare infrastructure, data localization requirements, commercial sequencing services, and competitive strategies shaping market growth. The study evaluates how domestic sequencing infrastructure, population-specific genomic databases, automated workflows, and bioinformatics capabilities are influencing the market. It also examines emerging opportunities in agriculture, livestock, fisheries, and aquaculture, where genomic technologies can support breeding, disease surveillance, crop improvement, and biodiversity research.

Market Dynamics

The continued expansion of Indonesia's national genomics program is one of the primary drivers of the NGS market. Government investment has substantially increased the country's sequencing infrastructure, with the installed base expanding from approximately 12 sequencing machines to around 60 machines. The Ministry of Health has added 48 whole-genome sequencing machines across national referral hospitals and established a network involving ten Ministry of Health vertical hospitals and ten specialized genomics centers. The broader laboratory network extends to 29 established laboratories, creating sustained demand for sequencing systems, proprietary consumables, sample preparation technologies, automation platforms, software, and genomic data analysis services.

The scale and continuity of Indonesia's national genomics program are expected to remain important sources of sequencing demand. Large-scale population genomics requires continuous sequencing activity rather than a one-time investment in instruments. The Ministry of Health has set an objective of sequencing 400,000 human genomes by 2030, indicating the substantial volume of sequencing activity expected as the country's genomics infrastructure continues to develop. This expansion is also expected to increase demand for data storage, bioinformatics, genomic interpretation, and laboratory support services.

The growing burden of cancer is another important factor supporting NGS adoption. According to IARC estimates, Indonesia recorded more than 400,000 new cancer cases in 2022. As cancer care increasingly incorporates molecular characterization, NGS can support the identification of actionable mutations, tumor profiling, hereditary cancer risk assessment, and treatment selection. The increasing clinical importance of precision oncology is therefore expected to create demand for targeted sequencing panels, sequencing consumables, molecular diagnostic workflows, and specialized bioinformatics services.

Indonesia's large and genetically diverse population also creates significant opportunities for population genomics and precision medicine. The development of population-specific genomic databases can improve the interpretation of genetic variants and support diagnostic and therapeutic approaches that better reflect the characteristics of Indonesian populations. Increasing volumes of genomic information are also creating demand for domestic data storage, processing, interpretation, and management capabilities.

Government requirements concerning health data processing are further influencing the structure of the market. Government Regulation 28 of 2024 requires health data and health information systems to be stored and processed within Indonesian jurisdiction. This requirement is encouraging healthcare organizations and sequencing providers to strengthen domestic sequencing, data storage, and bioinformatics capabilities. The resulting shift toward domestic genomic workflows is expected to create opportunities for local infrastructure providers, data-processing companies, sequencing laboratories, and bioinformatics solution providers.

Despite favorable market conditions, several challenges continue to influence NGS adoption in Indonesia. The high cost of whole-genome sequencing services and genomics research remains an important consideration, particularly for government-funded programs and healthcare institutions operating under budget constraints. Limited laboratory capacity, shortages of genomics and bioinformatics specialists, and gaps in digital infrastructure can also restrict the wider adoption of whole-genome sequencing. In addition, the limited inclusion of genomic diagnostics within national insurance benefits can constrain the adoption of certain clinical applications.

The market nevertheless presents substantial long-term opportunities. The expansion of sequencing into agriculture, livestock, fisheries, and aquaculture can create additional sources of demand beyond human healthcare. Indonesia's large agricultural and aquaculture sectors provide opportunities for genomic applications in crop improvement, disease surveillance, selective breeding, animal research, and biodiversity studies. These applications are less dependent on clinical reimbursement and can therefore provide additional growth opportunities for sequencing technology providers and commercial sequencing service companies.

The development of domestic bioinformatics and data analysis capabilities also represents a significant opportunity. As national genomics programs generate increasing volumes of genomic data, organizations require technologies capable of storing, processing, analyzing, and interpreting complex datasets within Indonesia. Companies offering genomic data analysis software, interpretation platforms, cloud infrastructure, and specialized bioinformatics services are therefore expected to benefit from the continued development of Indonesia's genomics ecosystem.

Segment Analysis

The report provides detailed market analysis across offering, application, and end user, enabling stakeholders to identify high-growth opportunities and evolving patterns of NGS adoption across Indonesia's healthcare, research, pharmaceutical, agricultural, and biotechnology sectors.

Based on offering, the market is segmented into sample preparation, sequencing, data analysis and bioinformatics, and commercial sequencing and outsourced services. Sample preparation includes kits and reagents and NGS workstations, while sequencing comprises NGS systems, consumables, and services. Data analysis and bioinformatics includes software and NGS informatics services, while commercial sequencing and outsourced services include whole-genome sequencing, whole-exome sequencing, targeted sequencing, RNA sequencing, and other commercial sequencing services. Sequencing represents a major component of the market due to continued investment in national sequencing infrastructure and the expansion of government-supported genomics programs. Data analysis and bioinformatics is expected to experience rapid growth as increasing sequencing activity generates greater demand for genomic data processing, interpretation, and management.

Based on application, the market is segmented into research and other applications and clinical applications. Research and other applications include drug discovery, agriculture and animal research, and other applications, while clinical applications include oncology, reproductive health, infectious diseases, rare diseases, and other clinical applications. Research and other applications currently represent an important source of NGS demand, supported by government-funded genomics programs and public research initiatives. Clinical applications are expected to continue expanding as sequencing becomes increasingly relevant to oncology, reproductive health, infectious disease surveillance, rare disease diagnosis, and precision medicine.

The report further analyzes the market across pharmaceutical and biotechnology companies, hospitals, clinical and reference laboratories, academic and research institutes, and other end users. Hospitals, clinical and reference laboratories represent an important component of the market due to the expansion of sequencing capabilities within major healthcare institutions and their participation in national genomics programs. Academic and research institutes also represent a significant source of demand for genomic research, population studies, and agricultural applications. Pharmaceutical and biotechnology companies are expected to increase their use of sequencing technologies for drug discovery, biomarker research, precision medicine, and other life science applications.

Regional Analysis

As this report focuses specifically on Indonesia, the regional assessment evaluates the country's NGS ecosystem by considering healthcare infrastructure, sequencing capacity, government genomics initiatives, research activity, laboratory capabilities, data processing requirements, regulatory conditions, and agricultural and aquaculture applications.

Major healthcare institutions and specialized genomics facilities currently represent important centers of sequencing activity in Indonesia. The national genomics program is coordinated through ten Ministry of Health vertical hospitals, supported by ten specialized genomics centers. The development of these facilities, together with the expansion of sequencing capacity across national referral hospitals, is strengthening access to genomic technologies and creating demand for sequencing consumables, sample preparation systems, data analysis platforms, and laboratory services.

The development of domestic sequencing infrastructure is also becoming increasingly important because of Indonesia's health data requirements. The country's requirement for health data to be stored and processed within Indonesian jurisdiction is encouraging healthcare organizations and sequencing providers to develop local data storage, processing, and bioinformatics capabilities. This is expected to support the development of domestic genomic workflows and reduce dependence on overseas facilities for selected sequencing and data analysis activities.

Indonesia's agricultural and aquaculture sectors provide additional opportunities for NGS adoption outside clinical applications. The country harvested approximately 10.05 million hectares of paddy and produced 53.14 million tons of paddy in 2024, while aquaculture production reached 6.37 million tons. These large production sectors create opportunities for genomic technologies in crop improvement, disease surveillance, selective breeding, animal health, and biodiversity research.

The continued development of genomics infrastructure across Indonesia is expected to improve access to NGS technologies while creating opportunities for sequencing technology manufacturers, commercial sequencing providers, bioinformatics companies, research organizations, hospitals, and other stakeholders. Differences in laboratory capabilities, specialist availability, digital infrastructure, and healthcare access across the country will remain important considerations influencing the pace of NGS adoption.

Competitive Landscape

The report presents a comprehensive evaluation of the competitive environment by examining the strategic positioning of leading NGS market participants, their sequencing platforms, consumable portfolios, sample preparation technologies, bioinformatics capabilities, commercial sequencing services, automation technologies, partnerships, acquisitions, product launches, geographic expansion initiatives, research and development investments, and recent business developments.

The Indonesia NGS market is consolidated and is led primarily by international sequencing and life science companies. Competitive benchmarking enables stakeholders to evaluate companies based on sequencing technologies, workflow integration, sample preparation capabilities, consumables, bioinformatics solutions, commercial sequencing services, automation, clinical applications, and ability to support large-scale government genomics programs.

Competition is increasingly influenced by government procurement, national genomics infrastructure development, local distribution partnerships, product launches, acquisitions, collaborations, and the development of integrated sequencing workflows. As Indonesia expands its domestic sequencing capacity, suppliers are increasingly required to compete not only on instrument performance but also on overall workflow economics, including sample preparation, consumables, automation, data analysis, and cost per sample.

The market is also witnessing increasing integration across the sequencing workflow. Leading suppliers are expanding beyond sequencing instruments into sample preparation, automation, multiomics, and bioinformatics solutions. This integrated approach aligns with the country's need to strengthen laboratory infrastructure, technical expertise, and genomic data-processing capabilities.

Key companies profiled in the report include MGI Tech Co., Ltd., Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., BGI Genomics Co., Ltd., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Revvity, Inc., Pacific Biosciences of California, Inc., Danaher Corporation, Oxford Nanopore Technologies plc, Eurofins Scientific SE, and Novogene Co., Ltd.

How This Report Helps

• Provides accurate market size estimates and long-term forecasts for the Indonesia next-generation sequencing market.
• Evaluates the impact of national genomics programs, population genomics, precision medicine, cancer burden, data localization requirements, and technological advancements on market growth.
• Identifies high-growth opportunities across offerings, applications, end users, clinical genomics, research, agriculture, livestock, fisheries, and aquaculture.
• Analyzes emerging technology trends, domestic sequencing infrastructure, bioinformatics development, data processing requirements, and government procurement dynamics shaping market growth.
• Evaluates the impact of Indonesia's health data processing requirements on domestic sequencing, genomic data storage, and bioinformatics capabilities.
• Benchmarks leading companies based on sequencing platforms, sample preparation technologies, consumables, automation capabilities, bioinformatics solutions, commercial sequencing services, and competitive positioning.
• Supports product development, investment planning, partnership evaluation, market entry, distribution strategy, and business expansion decisions.
• Delivers actionable market intelligence for sequencing technology manufacturers, diagnostic laboratories, hospitals, pharmaceutical companies, biotechnology companies, academic institutions, research organizations, agricultural companies, aquaculture companies, investors, distributors, and other stakeholders.

Key Questions Answered

• What is the current size of the Indonesia next-generation sequencing market, and how is it expected to evolve through 2036?
• Which healthcare, technological, governmental, regulatory, and economic factors are driving NGS market growth in Indonesia?
• What are the major drivers, restraints, opportunities, and challenges influencing NGS adoption in Indonesia?
• How is the expansion of Indonesia's national genomics program influencing demand for sequencing systems, consumables, sample preparation technologies, and bioinformatics solutions?
• What role will the government's objective of sequencing 400,000 human genomes by 2030 play in the development of the NGS market?
• How is the country's growing cancer burden influencing demand for molecular testing and precision oncology applications?
• What impact do Indonesia's health data localization requirements have on domestic sequencing, data storage, and bioinformatics capabilities?
• Which offering, application, and end-user segments are expected to experience the strongest growth during the forecast period?
• What opportunities exist for NGS technologies in agriculture, livestock, fisheries, aquaculture, and biodiversity research?
• How is the development of domestic genomic databases supporting population genomics and precision medicine in Indonesia?
• What factors are influencing workflow costs and government procurement decisions for NGS technologies?
• Who are the leading companies operating in the Indonesia NGS market, and what competitive strategies are they adopting?
• What recent product launches, partnerships, acquisitions, investments, collaborations, and technological developments are shaping the competitive landscape?
• How can stakeholders leverage market intelligence from this report to support investment decisions, product development, competitive benchmarking, market entry, and long-term business strategy?